PT  - JOURNAL ARTICLE
AU  - Farizano Salazar, Diego H.
AU  - Achinelli, Fernando
AU  - Colonna, Mariana
AU  - Perez, Lucía
AU  - Giménez, Analía A.
AU  - Ojeda, Maria Alejandra
AU  - Miranda Puente, Susana N.
AU  - Negrette, Lía Sánchez
AU  - Cañete, Florencia
AU  - Martelotte Ibarra, Ornela I.
AU  - Sanguineti, Santiago
AU  - Spatz, Linus
AU  - Goldbaum, Fernando A.
AU  - Massa, Carolina
AU  - Rivas, Marta
AU  - Pichel, Mariana
AU  - Hiriart, Yanina
AU  - Zylberman, Vanesa
AU  - Gallego, Sandra
AU  - Konigheim, Brenda
AU  - Fernandez, Francisco
AU  - Deprati, Matías
AU  - Roubicek, Ian
AU  - Giunta, Diego H.
AU  - Nannini, Esteban
AU  - Lopardo, Gustavo
AU  - Belloso, Waldo H.
AU  - ,
TI  - Safety and effectiveness of RBD-specific polyclonal equine F(ab′)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: a retrospective cohort study
AID  - 10.1101/2022.04.07.22273558
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.07.22273558
4099  - http://medrxiv.org/content/early/2022/04/17/2022.04.07.22273558.short
4100  - http://medrxiv.org/content/early/2022/04/17/2022.04.07.22273558.full
AB  - Passive immunotherapy has been evaluated as a therapeutic alternative for patients with COVID-19 disease. Equine polyclonal immunotherapy for COVID-19 (EPIC) showed adequate safety and potential efficacy in a clinical trial setting and obtained emergency use authorization in Argentina. We studied its utility in a real world setting with a larger population.Methods We conducted a retrospective cohort study at “Hospital de Campaña Escuela-Hogar” in Corrientes, Argentina, to assess safety and effectiveness of EPIC in hospitalized adults with severe COVID-19 pneumonia. Primary endpoints were 28-days all-cause mortality and safety. Mortality and improvement in modified WHO clinical scale at 14 and 21 days were secondary endpoints. Potential confounder adjustment was made by logistic regression weighted by the inverse of the probability of receiving the treatment (IPTW) and doubly robust approach.Results Clinical records of 395 exposed (EPIC) and 446 non-exposed (Controls) patients admitted between November 2020 and April 2021 were analyzed. Median age was 58 years and 56.8% were males. Mortality at 28 days was 15.7% (EPIC) vs. 21.5% (Control). After IPTW adjustment the OR was 0.66 (95 % CI: 0.46 - 0.96), P= 0.03. The effect was more evident in the subgroup who received two EPIC doses (complete treatment, n=379), OR: 0.58 (95% CI 0.39 to 0.85), P=0.005. Overall and serious adverse events were not significantly different between groups.Importance In this retrospective cohort study, EPIC showed adequate safety and effectiveness in the treatment of hospitalized patients with severe SARS-CoV-2 disease.Competing Interest StatementDHFS, FA, AAG, NAO, SNMP, LSN, FC, OIMI declare reimbursement for conduction of the observational study as investigators. EN, GL, WHB, DHG and LP report personal fees from Inmunova. SG and BK declare no competing interests.Clinical Protocols https://ClinicalTrials.gov Funding StatementInmunova SA and Laboratorios Elea-Phoenix SAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Boards from both the Hospital de Campanha Escuela-Hogar and the Hospital Italiano of Buenos Aires city, Argentina.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://ClinicalTrials.gov